Phaseline

Companies › Quratis

Quratis: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QTP101
Recombinant protein antigen (ID93) comprising four antigens from Mycobacterium tuberculosi
–Phase 1Tuberculosis, PulmonaryDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06714513QTP101Phase 1Tuberculosis, PulmonaryInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.